Predicta Biosciences Secures $5.2M to Transform the Diagnosis, Treatment and Monitoring of Blood Cancers

Read More →

Founded by leading cancer genomics researchers and clinicians, Predicta is developing a novel, non-invasive diagnostic for Multiple Myeloma

Jul 16, 2024

Read the full article in Buisnesswire here: https://www.businesswire.com/news/home/20240716981153/en/